Immune evasion in ebolavirus infections

Viral Immunology

Volumn 28, Issue 1, 2015, Pages 10-18

  Audet, Jonathan ^a   Kobinger, Gary P ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; GLUCOSE 1 PHOSPHATE; GLYCOPROTEIN; INTERFERON REGULATORY FACTOR 7; VIRUS PROTEIN;

ANTIBODY RESPONSE; CELL SURFACE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; GENE INTERACTION; GENOME; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MOLECULAR INTERACTION; MORTALITY; NONHUMAN; PROTEIN FUNCTION; REVIEW; RNA CAPPING; VIRUS DETECTION; ANIMAL; EBOLAVIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PRIMATE; VIROLOGY;

ANIMALIA; EBOLA VIRUS; PRIMATES;

ANIMALS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; PRIMATES; VIRAL PROTEINS;

EID: 84920837625     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0066     Document Type: Review

References (82)

1. Aleksandrowicz P, Marzi A, Biedenkopf N, et al. Ebola virus enters host cells by macropinocytosis and clathrinmediated endocytosis. J Infect Dis 2011;204:S957-S967.
2. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea-preliminary report. N Engl J Med 2014;1-8.
3. Bale S, Julien JP, Bornholdt ZA, et al. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog 2012;8: e1002916.
4. Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188:1630-1638.
5. Bowen ET, Platt GS, Simpson DI, McArdell LB, and Raymond RT. Ebola haemorrhagic fever: experimental infection of monkeys. Trans R Soc Trop Med Hyg 1978; 72:188-191.
6. Bray M, Davis K, Geisbert T, Schmaljohn C, and Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999;179 Suppl: S248-S258.
7. Bray M, and Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005;37:1560-1566.
8. Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011;0-6.
9. Carroll SA, Towner JS, Sealy TK, et al. Molecular evolution of viruses of the family Filoviridae based on 97 wholegenome sequences. J Virol 2013;87:2608-2616.
10. Chandran K, Sullivan NJ, Felbor U, Whelan SP, and Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005;308: 1643-1645.
11. Chang T-H, Kubota T, Matsuoka M, et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009;5: e1000493.
12. Dye JM, Herbert AS, Kuehne AI, et al. Pratt. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012;109:5034-5039.
13. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006;2:e73.
14. Feldmann H, and Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849-862.
15. Feldmann H, Jones S, Klenk H-D, and Schnittler H-J. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003;3: 677-685.
16. Feldmann H, Volchkov VE, Volchkova VA, Ströher U, and Klenk HD. Biosynthesis and role of filoviral glycoproteins. J Gen Virol 2001;82:2839-2848.
17. Fisher-Hoch SP, Brammer TL, Trappier SG, et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 1992;166:753-763.
18. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, and Bates P. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 2010;6:e1001098.
19. Friedrich BM, Trefry JC, Biggins JE, et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 2012;4:1619-1650.
20. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003;163:2347-2370.
21. Gnirß K, Fiedler M, Krämer-Kühl A, et al. Analysis of determinants in filovirus glycoproteins required for tetherin antagonism. Viruses 2014;6:1654-1671.
22. Guenno LB, Formenty P, Formentry P, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995;345:1271-1274.
23. Halfmann P, Neumann G, and Kawaoka Y. The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogenactivated protein kinase. J Infect Dis 2011;204 Suppl:S953-S956.
24. Hayes CG, Burans JP, Ksiazek TG, et al. Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus. Am J Trop Med Hyg 1992; 46:664-671.
25. Hoenen T, Groseth A, Falzarano D, and Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 2006;12:206-215.
26. Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011;7:e1001258.
27. Iwasa A, HalfmannP, Noda T, et al. Contribution of Sec61a to the life cycle of Ebola virus. J Infect Dis 2011;204 Suppl: S919-S926.
28. Iwasa A, Shimojima M, and Kawaoka Y. sGP serves as a structural protein in Ebola virus infection. J Infect Dis 2011;204 Suppl:S897-S903.
29. Johnson KM, Lange JV, Webb PA, and Murphy FA. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1977;309:569-571.
30. Kaletsky RL, Francica JR, Agrawal-Gamse C, and Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 2009;106:2886-2891.
31. Kash JC, Mühlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola-and Marburg viruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006; 80:3009-3020.
32. Kimberlin CR, Bornholdt ZA, Li S, Woods VL, MacRae IJ, and Saphire EO. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A 2010;107:314-319.
33. Kobinger GP, Leung A, Neufeld J, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 2011;204:200-208.
34. Kubota T, Matsuoka M, Chang T-H, et al. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J Biol Chem 2008;283:25660-25670.
35. Kugelman JR, Lee MS, Rossi CA, et al. Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One 2012;7:e50316.
36. Kühl A, Banning C, Marzi A, et al. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis 2011;204 Suppl:S850-S860.
37. Lee JE, Fusco ML, Hessell AJ, et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008;454:177-182.
38. Leroy EM, Epelboin A, Mondonge V, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 2009;9:723-728.
39. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575-576.
40. Leung DW, Ginder ND, Fulton DB, et al. Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A 2009;106:411-416.
41. Leung DW, Shabman RS, Farahbakhsh M, et al. Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol 2010;399:347-357.
42. Leung LW, Martinez O, Reynard O, Volchkov VE, and Basler CF. Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry. J Infect Dis 2011;204 Suppl:S973-S977.
43. Leung LW, Park M-S, Martinez O, Valmas C, López CB, and Basler CF. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol 2011;89:792-802.
44. Lubaki NM, Ilinykh P, Pietzsch C, et al. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol 2013;87:7471-7485.
45. MacNeil A, Farnon EC, Morgan OW, et al. Filovirus outbreak detection and surveillance: lessons from Bundibugyo. J Infect Dis 2011;204 Suppl:S761-S767.
46. MacNeil A, Farnon EC, Wamala J, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 2010;16:1969-1972.
47. Marzi A, Möller P, Hanna SL, et al. Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis 2007;196 Suppl:S237-S246.
48. Mateo M, Carbonnelle C, Reynard O, et al. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J Infect Dis 2011;204 Suppl:S1011-S1020.
49. Miranda ME, Ksiazek TG, Retuya TJ, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 1999;179 Suppl:S115-S119.
50. Miranda ME, and Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 2011;204 Suppl:S757-S760.
51. Mohan GS, Li W, Ye L, Compans RW, and Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 2012;8:e1003065.
52. Noyori O, Matsuno K, Kajihara M, et al. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Virology 2013;446:152-161.
53. Noyori O, Nakayama E, Maruyama J, Yoshida R, and Takada A. Suppression of Fas-mediated apoptosis via steric shielding by filovirus glycoproteins. Biochem Biophys Res Commun 2013;441:994-998.
54. Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012;109:18030-18035.
55. Papenfuss AT, Baker ML, Feng Z-P, et al. The immune gene repertoire of an important viral reservoir, the Australian black flying fox. BMC Genomics 2012;13:261.
56. Pattyn S, Van Der Groen G, Courteille G, Jacob W, and Piot P. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet 1977;309:573-574.
57. Prins KC, Cárdenas WB, and Basler CF. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009;83:3069-3077.
58. ProMED. Ebola virus disease-Democratic Republic of Congo (24): (Orientale Province). ProMED Mail 2012.
59. Qiu X, Audet J, Wong G, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012;4:138ra81.
60. Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013;3:3365.
61. Qiu X, Wong G, Fernando L, et al. mAbs and Ad-vectored IFN-A therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013;5:207ra143.
62. Radoshitzky SR, Warfield KL, Chi X, et al. Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. J Virol 2011;85:8502-8513.
63. Raymond JL, Bradfute S, and Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011;204 Suppl: S986-S990.
64. Reid SP, Valmas C, Martinez O, Sanchez FM, and Basler CF. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007;81:13469-13477.
65. Reynard O, Reid SP, Page A, et al. Unconventional secretion of Ebola virus matrix protein VP40. J Infect Dis 2011;204 Suppl:S833-S839.
66. Roddy P, Colebunders R, Jeffs B, Palma PP, Herp MV, and Borchert M. Filovirus hemorrhagic Fever outbreak case management: a review of current and future treatment options. J Infect Dis 2011;204 Suppl:S791-S795.
67. Sanchez A, Geisbert TW, and Feldmann H. Filoviridae: Marburg and ebola viruses. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields Virol. Philadelphia: Lippincott, Williams & Wilkins, 2007:1409-1448.
68. Sanchez A, Trappier SG, Mahy BW, Peters CJ, and Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996;93: 3602-3607.
69. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, and Peters CJ. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 1998;72:6442-6447.
70. Shabman RS, Gulcicek EE, Stone KL, and Basler CF. The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin a1 and partially alters its nuclear import. J Infect Dis 2011;204 Suppl:S904-S910.
71. Shabman RS, Leung DW, Johnson J, et al. DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis 2011;204 Suppl:S911-S918.
72. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, and Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002;76:2518-2528.
73. Valmas C, Grosch MN, Schümann M, et al. Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. PLoS Pathog 2010;6:e1000721.
74. Volchkova VA, Dolnik O, Martinez MJ, Reynard O, and Volchkov VE. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis 2011;204 Suppl:S941-S946.
75. Wahl-Jensen V, Kurz SK, Hazelton PR, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005;79:2413-2419.
76. Wahl-Jensen VM, Afanasieva TA, Seebach J, Ströher U, Feldmann H, and Schnittler H-J. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005;79:10442-10450.
77. Weissenhorn W, Carf? A, Lee KH, Skehel JJ, and Wiley DC. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 1998;2:605-616.
78. Wolf K, Beimforde N, Falzarano D, Feldmann H, and Schnittler H-J. The Ebola virus soluble glycoprotein (sGP) does not affect lymphocyte apoptosis and adhesion to activated endothelium. J Infect Dis 2011;204 Suppl: S947-S952.
79. Yuan J, Zhang Y, Li J, Zhang Y, Wang L-F, and Shi Z. Serological evidence of ebolavirus infection in bats, China. Virol J 2012;9:236.
80. Zhang AP, Abelson DM, Bornholdt ZA, Liu T, Woods VL, and Saphire EO. The ebolavirus VP24 interferon antagonist: know your enemy. Virulence 2012;3:440-445.
81. Zhang AP, Bornholdt ZA, Liu T, et al. The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog 2012;8:e1002550.
82. Zhang G, Cowled C, Shi Z, et al. Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science 2013;339:456-460.